Real-World Experience With Maribavir for Treatment of Cytomegalovirus Infection in High-Risk Solid Organ Transplant Recipients
Resource type
Journal Article
Authors/contributors
- Ni, Bin (Author)
- Wolfe, Cameron R (Author)
- Arif, Sana (Author)
- Carugati, Manuela (Author)
- Heldman, Madeleine R (Author)
- Messina, Julia A (Author)
- Miller, Rachel A (Author)
- Saullo, Jennifer L (Author)
- Baker, Arthur W (Author)
- Maziarz, Eileen K (Author)
Title
Real-World Experience With Maribavir for Treatment of Cytomegalovirus Infection in High-Risk Solid Organ Transplant Recipients
Abstract
Abstract
We evaluated use of maribavir (MBV) for treatment of 15 episodes of refractory/resistant cytomegalovirus infection in 13 solid organ transplant recipients. Treatment failure due to treatment-emergent MBV resistance or early virological recurrence after MBV discontinuation occurred in 7 (47%) episodes. Sustained viral clearance was achieved in 6 (40%) episodes.
Publication
Open Forum Infectious Diseases
Volume
11
Issue
7
Pages
ofae335
Date
2024-06-28
Language
en
ISSN
2328-8957
Accessed
7/9/24, 8:11 PM
Library Catalog
DOI.org (Crossref)
Citation
Ni, B., Wolfe, C. R., Arif, S., Carugati, M., Heldman, M. R., Messina, J. A., Miller, R. A., Saullo, J. L., Baker, A. W., & Maziarz, E. K. (2024). Real-World Experience With Maribavir for Treatment of Cytomegalovirus Infection in High-Risk Solid Organ Transplant Recipients. Open Forum Infectious Diseases, 11(7), ofae335. https://doi.org/10.1093/ofid/ofae335
Link to this record